Abstract The type III TGF-β receptor has potential therapeutic and prognostic potential in breast cancer.
The finding highlighted by the work of Pang et al. (2014) supports and extends work done at the RNA level showing that lower expression of the type III TGF-β receptor (TBR3), or β-glycan predicts a poor outcome and increased invasiveness of breast cancer. TBR3 acts as a co-receptor for TGFβ isoforms. Although at first seemingly counter-intuitive, a possible clarifying mechanism for this observation was suggested in the discussion that TBR3 can undergo ectodomain shedding, and thereby act as a decoy receptor. This notion is interesting and suggests that development of a TBR3 mimetic could possibly be considered as a breast cancer therapeutic.
